CRISPR Therapeutics AG reports developments in gene-based medicines built around CRISPR/Cas9 gene editing, cell therapy, in vivo editing and siRNA programs. Recurring updates cover CASGEVY, developed with Vertex for severe sickle cell disease and transfusion-dependent beta thalassemia, as well as pipeline work in cardiovascular disease, autoimmune disease, oncology, rare disease and Type 1 diabetes.
Company news also includes financial results, business updates, investor conference presentations, manufacturing and platform disclosures, collaborations such as Sirius Therapeutics, and capital actions involving common shares or convertible senior notes.
CRISPR Therapeutics (Nasdaq: CRSP) announced that Chief Operating Officer Julianne Bruno will step down from her position effective April 11, 2025, to pursue external opportunities. Bruno has served the company for six years, during which her leadership was important in advancing the company's hematology and oncology programs. CEO Samarth Kulkarni acknowledged her contributions in maturing the company's operating model and various cross-functional initiatives.
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's senior management team will deliver a presentation on March 3, 2025, at 10:30 a.m. ET.
Investors and interested parties can access a live webcast of the fireside chat through the company's website under the 'Events & Presentations' section. The presentation recording will remain available for replay on the company's website for 14 days following the event.
CRISPR Therapeutics reports Q4 and full year 2024 results, highlighting significant progress across its portfolio. The company's CASGEVY® treatment continues to gain momentum with more than 50 authorized treatment centers activated globally and over 50 patients having cells collected across all regions by end of 2024.
The company maintains a strong financial position with $1.9 billion in cash and equivalents as of December 31, 2024. Q4 2024 financial results show R&D expenses of $82.2 million (down from $95.1 million in Q4 2023) and G&A expenses of $18.1 million. The company reported a net loss of $37.3 million for Q4 2024, compared to net income of $89.3 million in Q4 2023.
Key developments include ongoing clinical trials for next-generation CAR T products CTX112™ and CTX131™, and in vivo gene editing candidates CTX310™ and CTX320™. The company also established a strategic partnership with Nkure Therapeutics for CTX112 development in India.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines for serious diseases, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The company's senior management team will deliver a presentation on Wednesday, February 5, 2025, at 2:00 p.m. ET.
The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section. Interested parties can view the fireside chat through the investor relations portal at https://crisprtx.gcs-web.com/events. The recording will remain available for replay on the company's website for 14 days after the presentation.
CRISPR Therapeutics (Nasdaq: CRSP) has outlined its strategic priorities and anticipated milestones for 2025. The company is starting the year with approximately $1.9 billion in cash and marketable securities, driven by the successful launch of CASGEVY®. CASGEVY has seen strong global demand, with over 50 patients initiating cell collection and more than 50 Authorized Treatment Centers (ATCs) established globally.
Key priorities for 2025 include advancing pipeline candidates such as CTX112™ in oncology and autoimmune diseases, and CTX310™ and CTX320™ in cardiovascular indications. The company also focuses on next-generation gene editing and lipid nanoparticle (LNP) delivery platforms.
Significant updates are expected in 2025, including quarterly updates on CASGEVY, clinical data updates for CTX310 and CTX320 in the first half of the year, and a broad update on CTX112 in mid-2025. Additional updates are anticipated for CTX131 and regenerative medicine programs.
CRISPR Therapeutics has made progress in its immuno-oncology and autoimmune disease programs, with CTX112 showing strong efficacy in Phase 1/2 trials. The company also plans to expand trials for CTX112 in systemic lupus erythematosus, systemic sclerosis, and inflammatory myositis. Furthermore, advancements are being made in in vivo cardiovascular programs and regenerative medicine, including trials for Type 1 diabetes treatments.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company dedicated to developing transformative gene-based medicines for serious diseases, announced that its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference.
The presentation is scheduled for Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the 'Events & Presentations' page in the Investors section of the company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the company's website for 14 days following the presentation.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on gene-based medicines for serious diseases, announced the proposed election of Briggs Morrison, M.D. to its Board of Directors at the upcoming annual general meeting. CEO Samarth Kulkarni emphasized Dr. Morrison's extensive pharmaceutical industry experience and clinical development expertise as valuable assets for advancing the company's innovative platform and pipeline.
Dr. Morrison, currently the CEO and Board member of Crossbow Therapeutics, Inc., expressed enthusiasm about joining CRISPR Therapeutics. With over 30 years in the pharmaceutical and biotechnology sectors, he has held executive roles at Syndax Pharmaceuticals, AstraZeneca, Pfizer, and Merck. He has overseen clinical development from Phase 1 to approval for several drugs, including Tagrisso®, Imfinzi®, and Lynparza®.
Dr. Morrison also serves on the boards of various biotechnology companies and is an Entrepreneur Partner at MPM BioImpact. He holds a B.S. in Biology from Georgetown University and an M.D. from the University of Connecticut.
CRISPR Therapeutics presented data from their Phase 1/2 clinical trial of CTX112™, a next-generation CD19 allogeneic CAR T cell therapy, showing promising results in treating relapsed or refractory B-cell malignancies. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for treating R/R follicular lymphoma and marginal zone lymphoma.
Key findings include:
- 67% objective response rate across all dose levels
- 50% complete response rate
- Well-tolerated safety profile with no Grade ≥3 infections
- Five patients achieved responses lasting over 6 months
The trial involved 12 subjects treated with varying doses, demonstrating dose-dependent efficacy. CTX112 is also being tested in a Phase 1 trial for systemic lupus erythematosus, with potential expansion into other autoimmune indications. A broader update across indications is expected in mid-2025.
CRISPR Therapeutics (Nasdaq: CRSP) has announced its participation in the upcoming Jefferies London Healthcare Conference. CEO and Chairman Samarth Kulkarni, Ph.D., will deliver a presentation on Wednesday, November 20, 2024, at 4:00 p.m. GMT. The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section, with a replay available for 14 days afterward. CRISPR Therapeutics specializes in developing transformative gene-based medicines for serious diseases.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced that their CEO and Chairman, Samarth Kulkarni, Ph.D., will present at the Guggenheim Inaugural Healthcare Innovation Conference. The presentation is scheduled for Tuesday, November 12, 2024, at 2:00 p.m. ET.
A live webcast of the fireside chat will be accessible through the company's website's 'Events & Presentations' page in the Investors section. The webcast recording will remain available for 14 days after the presentation.